SG11201808138YA - Substituted indole derivatives as dengue viral replication inhibitors - Google Patents

Substituted indole derivatives as dengue viral replication inhibitors

Info

Publication number
SG11201808138YA
SG11201808138YA SG11201808138YA SG11201808138YA SG11201808138YA SG 11201808138Y A SG11201808138Y A SG 11201808138YA SG 11201808138Y A SG11201808138Y A SG 11201808138YA SG 11201808138Y A SG11201808138Y A SG 11201808138YA SG 11201808138Y A SG11201808138Y A SG 11201808138YA
Authority
SG
Singapore
Prior art keywords
leuven
international
dengue viral
compounds
janssen
Prior art date
Application number
SG11201808138YA
Inventor
Dorothée Alice Marie-Eve Bardiot
Jean-François Bonfanti
Bart Rudolf Romanie Kesteleyn
Arnaud Didier M Marchand
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of SG11201808138YA publication Critical patent/SG11201808138YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111011110110101011111010111110110111100111111110011111111111111011111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/167950 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every CO7D 209/14 (2006.01) A61P 31/14 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4045 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2017/057660 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 31 March 2017 (31.03.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 16163312.8 31 March 2016 (31.03.2016) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicants: JANSSEN PHARMACEUTICALS, INC. GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [US/US]; 1125 Trenton-Harbourton Road, Titusville, NJ TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, New Jersey 08560 (US). KATHOLIEKE UNI- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, VERSITEIT LEUVEN [BE/BE]; Waaistraat 6, bus 5105, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 3000 Leuven (BE). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: BARDIOT, Dorothee Alice Marie-Eve; c/o SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — Cistim Leuven vzw Gaston Geenslaan 2, 3001 Leuven GW, KM, ML, MR, NE, SN, TD, TG). — (Heverlee) (BE). BONFANTI, Jean-Francois; c/o Declarations under Rule 4.17: _ Janssen-Cilag 1 rue Camille Desmoulins, TSA 91003, — as to applicant's entitlement to apply for and be granted a 92787 Issy-les-Moulineaux Cedex 9 (FR). KESTELEYN, 4.1700) = Bart Rudolf Romanie; Pharmaceutica NV patent (Rule c/o Janssen Turnhoutseweg 30, 2340 Beerse MARCHAND, Published: (BE). = Arnaud Didier M; c/o Cistim Leuven vzw Gaston Geens- = - with international search report (Art. 21(3)) = laan 2, 3001 Leuven (Heverlee) (BE). RABOISSON, Pierre Jean-Marie Bernard; c/o Janssen Pharmaceutica — with sequence listing part of description (Rule 5.2(a)) NV Turnhoutseweg 30, 2340 Beerse (BE). (74) Agent: VERBERCKMOES, Filip; J&J Patent Law De- = partment Turnhoutseweg 30, 2340 Beerse (BE). = = = = = = = = 1-1 © kr) 0\ IN 1-1 (54) Title: SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS 1-1 C (57) : The present invention concerns substituted indole derivatives, methods to prevent or treat dengue viral infections by N using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or 0 prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination prepara- tions of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
SG11201808138YA 2016-03-31 2017-03-31 Substituted indole derivatives as dengue viral replication inhibitors SG11201808138YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163312 2016-03-31
PCT/EP2017/057660 WO2017167950A1 (en) 2016-03-31 2017-03-31 Substituted indole derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
SG11201808138YA true SG11201808138YA (en) 2018-10-30

Family

ID=55650292

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808138YA SG11201808138YA (en) 2016-03-31 2017-03-31 Substituted indole derivatives as dengue viral replication inhibitors

Country Status (26)

Country Link
US (1) US10646469B2 (en)
EP (1) EP3436435B1 (en)
JP (1) JP6888021B2 (en)
KR (1) KR102359743B1 (en)
CN (1) CN108884033B (en)
AU (1) AU2017242893A1 (en)
BR (1) BR112018068676A2 (en)
CA (1) CA3013405A1 (en)
CL (1) CL2018002729A1 (en)
CO (1) CO2018009559A2 (en)
CR (1) CR20180495A (en)
DK (1) DK3436435T3 (en)
EA (1) EA201892214A1 (en)
EC (1) ECSP18073245A (en)
ES (1) ES2882488T3 (en)
HK (1) HK1258142A1 (en)
HR (1) HRP20210847T1 (en)
HU (1) HUE054936T2 (en)
IL (1) IL261944A (en)
LT (1) LT3436435T (en)
MX (1) MX2018011784A (en)
PH (1) PH12018502015A1 (en)
SG (1) SG11201808138YA (en)
SI (1) SI3436435T1 (en)
WO (1) WO2017167950A1 (en)
ZA (1) ZA201806473B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (en) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JOP20160198B1 (en) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JO3633B1 (en) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
CR20180494A (en) 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc DERIVATIVES OF INDOL SUBSTITUTES SUBSTITUTED AS INHIBITORS OF THE VIRIC REPLICATION OF DENGUE
JOP20170069B1 (en) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
JOP20180026A1 (en) 2017-03-31 2019-01-30 Univ Leuven Kath Substituted indoline derivatives as dengue viral replication inhibitors
JOP20180025B1 (en) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
PE20200604A1 (en) 2017-05-22 2020-03-10 Janssen Pharmaceuticals Inc INDOLINE DERIVATIVES SUBSTITUTED AS INHIBITORS OF DENGUE VIRAL REPLICATION
EA039702B1 (en) 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Substituted indoline derivatives as dengue viral replication inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2005520795A (en) 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Purine analogs having HSP90 inhibitory activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
MX2007008587A (en) 2005-01-14 2007-09-07 Genelabs Tech Inc Indole derivatives for treating viral infections.
JP2008530124A (en) 2005-02-09 2008-08-07 ミジェニックス インコーポレイテッド Compositions and methods for treating or preventing flavivirus infections
BRPI0909985A2 (en) 2008-06-03 2015-08-25 Siga Technologies Inc Pharmaceutical composition and method for the treatment or prophylaxis of a viral infection or associated disease
WO2010021878A1 (en) * 2008-08-19 2010-02-25 Janssen Pharmaceutica Nv Cold menthol receptor antagonists
WO2010091413A1 (en) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
KR20120123678A (en) 2010-01-15 2012-11-09 길리애드 사이언시즈, 인코포레이티드 Inhibitors of flaviviridae viruses
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
ES2655518T3 (en) 2013-10-23 2018-02-20 Janssen Sciences Ireland Uc Carboxamide derivatives and their use as medicines for the treatment of hepatitis B
US9777001B2 (en) 2014-01-31 2017-10-03 Bristol-Myers Squibb Company Macrocycles with aromatic P2′ groups as factor xia inhibitors
NO2721243T3 (en) 2014-10-01 2018-10-20
PT3201177T (en) 2014-10-01 2019-02-12 Univ Leuven Kath Mono- or di-substituted indoles as dengue viral replication inhibitors
ES2714074T3 (en) 2014-10-01 2019-05-27 Janssen Pharmaceuticals Inc Mono- or disubstituted indole derivatives as inhibitors of dengue virus replication
JOP20150335B1 (en) 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc indole derivatives as dengue viral replication inhibitors
AR103680A1 (en) 2015-02-23 2017-05-24 Lilly Co Eli BACE1 SELECTIVE INHIBITORS
JOP20160086B1 (en) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JO3633B1 (en) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JOP20160198B1 (en) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
CA3002214C (en) 2015-11-03 2022-01-04 Zoetis Services Llc Sol-gel polymer composites and uses thereof
UY37174A (en) 2016-03-31 2017-10-31 Takeda Pharmaceuticals Co A HETEROCYCLIC COMPOUND THAT HAS AN INHIBITING ACTION OF MONOACILGLICEROL LIPASA
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
CR20180518A (en) 2016-04-01 2019-04-25 Kite Pharma Inc FLT3 CHEMICAL RECEPTORS AND SAME USE METHODS
JOP20170069B1 (en) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
EP3436018A4 (en) 2016-04-01 2019-11-13 Signal Pharmaceuticals, LLC Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CR20180494A (en) 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc DERIVATIVES OF INDOL SUBSTITUTES SUBSTITUTED AS INHIBITORS OF THE VIRIC REPLICATION OF DENGUE
CN109641008B (en) 2016-04-01 2021-03-23 凯德药业股份有限公司 Chimeric receptors and methods and uses thereof
IL261941B2 (en) 2016-04-01 2023-11-01 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
BR112018068851B1 (en) 2016-04-01 2022-11-22 Basf Se COMPOUND OF FORMULA I, COMPOSITION, METHODS FOR COMBAT OR CONTROL OF INVERTEBRATE PEST AND FOR PLANT PROTECTION, COATED SEED AND USE OF AT LEAST ONE COMPOUND
JOP20180025B1 (en) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
JOP20180026A1 (en) 2017-03-31 2019-01-30 Univ Leuven Kath Substituted indoline derivatives as dengue viral replication inhibitors
EA039702B1 (en) 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Substituted indoline derivatives as dengue viral replication inhibitors
PE20200604A1 (en) 2017-05-22 2020-03-10 Janssen Pharmaceuticals Inc INDOLINE DERIVATIVES SUBSTITUTED AS INHIBITORS OF DENGUE VIRAL REPLICATION

Also Published As

Publication number Publication date
EA201892214A1 (en) 2019-03-29
CR20180495A (en) 2018-12-06
IL261944A (en) 2018-10-31
EP3436435B1 (en) 2021-05-12
HRP20210847T1 (en) 2021-07-23
EP3436435A1 (en) 2019-02-06
BR112018068676A2 (en) 2019-01-15
US10646469B2 (en) 2020-05-12
CO2018009559A2 (en) 2018-09-20
JP6888021B2 (en) 2021-06-16
KR20180130498A (en) 2018-12-07
ZA201806473B (en) 2020-05-27
ECSP18073245A (en) 2018-10-31
CL2018002729A1 (en) 2018-11-23
SI3436435T1 (en) 2021-08-31
PH12018502015A1 (en) 2019-07-15
US20190274999A1 (en) 2019-09-12
KR102359743B1 (en) 2022-02-07
MX2018011784A (en) 2019-02-13
HK1258142A1 (en) 2019-11-08
JP2019510024A (en) 2019-04-11
CN108884033B (en) 2021-03-09
CA3013405A1 (en) 2017-10-05
HUE054936T2 (en) 2021-10-28
ES2882488T3 (en) 2021-12-02
DK3436435T3 (en) 2021-08-09
LT3436435T (en) 2021-08-25
WO2017167950A1 (en) 2017-10-05
AU2017242893A1 (en) 2018-08-09
CN108884033A (en) 2018-11-23

Similar Documents

Publication Publication Date Title
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same